Back to Search
Start Over
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
- Source :
-
JNCI cancer spectrum [JNCI Cancer Spectr] 2022 Mar 02; Vol. 6 (2). - Publication Year :
- 2022
-
Abstract
- Urologists are increasingly prescribing oral targeted therapies to patients with advanced prostate cancer. Concurrent with this trend, urology practices are allowing patients to fill their prescription onsite or through a pharmacy established by the practice. We examined prescription patterns for abiraterone or enzalutamide between eventually dispensing single-specialty urology practices, nondispensing single-specialty urology practices, and multispecialty practices using a 20% random sample of the 2013-2017 national Medicare claims. We determined physician dispensing through manual search of publicly available information. From 2015 through 2017, higher percentages of patients managed by eventually dispensing single-specialty urology practices had a filled prescription of abiraterone or enzalutamide compared with patients managed in nondispensing single-specialty urology practices (eg, in 2017, 8.9%, 95% confidence interval = 7.3% to 10.9%, vs 5.9%, 95% confidence interval = 5.0% to 7.0%, respectively; 2-sided Pā<ā.001). Insofar as physician dispensing is associated with higher use of abiraterone or enzalutamide, it may represent a means to improve treatment access.<br /> (© The Author(s) 2022. Published by Oxford University Press.)
Details
- Language :
- English
- ISSN :
- 2515-5091
- Volume :
- 6
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- JNCI cancer spectrum
- Publication Type :
- Academic Journal
- Accession number :
- 35603854
- Full Text :
- https://doi.org/10.1093/jncics/pkac023